BOB体育

Skip to main content
(352) 294-5757

Barry J Byrne, MD, PhD

Pediatric Cardiologist

Photo of Barry J Byrne
(352) 294-5757 MyUFHealth

Research at a glance

Top areas of exploration

  • Genetic Therapy , 86 publications
  • Genetic Vectors , 80 publications
  • Glycogen Storage Disease Type II , 60 publications
  • Muscle, Skeletal , 41 publications

Research activity

367 publications

22,185 citations

Why is this important?

Active clinical trials

Pfizer Early Stage GT

The study will evaluate the safety and dystrophin expression following gene therapy in boys with Duchenne Muscular Dystrophy (DMD). It is a single-arm, non-randomized, open-label study

Investigator
Barry J Byrne
Status
Accepting Candidates
Ages
2 Years - 3 Years
Sexes
Male
ATB200-08

This is a Phase 3, open-label, multicenter study to evaluate the safety, efficacy, PK, PD, and immunogenicity of cipaglucosidase alfa/miglustat treatment in ERT-experienced and ERT-na茂ve pediatric subjects with IOPD.

Investigator
Barry J Byrne
Status
Accepting Candidates
Ages
N/A - 17 Years
Sexes
All
TECPR2 Obs

The purpose of this study is to learn more about the disease progression in patients with a TECPR2 mutation.

Investigator
Barry J Byrne
Status
Accepting Candidates
Ages
18 Months - 12 Years
Sexes
All

My publications

367 publications

2025

Cardiopulmonary exercise testing as an integrative approach to explore physiological limitations in Duchenne muscular dystrophy.

Journal of neuromuscular diseases

鈥�

2025

Clinical advances in gene, cell, and RNA therapies.

Molecular therapy : the journal of the American Society of Gene Therapy

鈥�

2025

Correction: Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02)

Journal of Neurology

鈥�

2025

Current clinical applications of AAV-mediated gene therapy

Molecular Therapy

2025

Effect of Tadalafil on cardiac function and left ventricular dimensions in Duchenne muscular dystrophy: safety and cardiac MRI substudy results from a randomized, placebo-controlled trial.

BMC cardiovascular disorders

鈥�